Data are n(%). Adverse events had an overall incidence /H113505% in any treatment arm and a higher incidence in an exenatide arm for the intent-to-treat population.Exenatide and glycemic control 1098 DIABETES CARE,VOLUME 28, NUMBER 5, M AY2005Downloaded from http://diabetesjournals.org/care/article-pdf/28/5/1092/566577/zdc0050500 092.pdf by guest on 17 January 2024